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Abstract
Background: Pituitary cysts have been speculated to cause
endocrinopathies. We sought to describe the prevalence and
volumetry of pituitary cysts in patients with growth hormone
deficiency (GHD) and idiopathic short stature (ISS).
Methods: Six hundred and eighteen children evaluated
for growth failure at the Division of Pediatric Endocrinology at New York Medical College between the years 2002
and 2012, who underwent GH stimulation testing and had
a brain magnetic resonance imaging (MRI) prior to initiating GH treatment were randomly selected to be a part
of this study. High resolution MRI was used to evaluate
the pituitary gland for size and the presence of a cyst.
Cyst prevalence, cyst volume and percentage of the gland
occupied by the cyst (POGO) were documented.
Results: Fifty-six patients had a cyst, giving an overall
prevalence of 9.1%. The prevalence of cysts in GHD
patients compared to ISS patients was not significant
(13.5% vs. 5.7%, p = 0.46). Mean cyst volume was greater
in GHD patients than ISS patients (62.0 mm3 vs. 29.4 mm3,
p = 0.01). POGO for GHD patients was significantly
greater (p = 0.003) than for ISS patients (15.3% ± 12.8 vs.
7.1% ± 8.0). Observers were blinded to patient groups.
Conclusions: GHD patients had a significantly greater
volume and POGO compared to ISS patients. This raises
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the question of whether cysts are implicated in the
pathology of growth failure.
Keywords: endocrinopathy; growth disorders; growth
hormone deficiency; growth hormone stimulation test;
hypopituitarism; magnetic resonance imaging; pituitary;
pituitary disease; pituitary volume; short stature.

Introduction
High resolution magnetic resonance imaging (MRI) evaluation of the pituitary gland has become essential in the
assessment of the growth hormone deficient (GHD) child
[1–3]. This new MRI technique allows for greater detailed
observations to be made [4–6]. As a result, the endocrinologist may discover new and more frequent radiographic findings, including pituitary cysts [7–9]. We have
previously shown a 14.6% prevalence of pituitary cysts in
pediatric patients [Abstract: Incidence and volumetry of
pituitary cysts in normal children]. One could easily speculate that compression of the pituitary by cysts may cause
dysfunction in secretion in the somatotrophs and other
cells of the pituitary gland [10–12]. This study sought to
compare the prevalence and volumetry of pituitary cysts
between GHD and idiopathic short stature (ISS) children.

Subjects and methods
Subjects
All children evaluated for growth failure seen in the Division of Pediatric Endocrinology at New York Medical College from 2002 to 2012,
who had a bone age demonstrating open growth plates and had high
resolution MRI and GH stimulation testing performed were considered for this study. Growth failure was defined as having a height less
than 2.0 standard deviations below the mean on the Centers for Disease Control (CDC) growth curve, a subnormal growth velocity for at
least 6 months and/or a predicted adult height greater than 5.08 cm
discrepant from the mid-parental height. A GH peak of less than or
equal to 10 ng/mL on stimulation was defined as GHD. Those with
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levels greater than 10 ng/mL were classified as ISS. The secretagogues
utilized during the GH stimulation test were clonidine and levodopa.
Clonidine was administered at 0.004 mg/kg by mouth with 0.05
or 0.1 mg tablet, and 7–10 mg/kg of levodopa was administered by
mouth with 125, 250, 375, or 500 mg tablet. GH levels were measured
at our in-house endocrine laboratory via the chemiluminescent assay
technique [13]. Patients were separated into two groups. Group 1 was
considered the prepubertal patients, as defined by an age ≤11 years.
Group 2 was considered the pubertal patients, as defined by an age
>11 years. Patients with Turner syndrome, SHOX gene mutation,
Cushing’s syndrome, hypothyroidism, other anterior pituitary hormone deficiencies and malnutrition were excluded from this study.
As this was a retrospective study of pre-existing data accumulated in
our division, it was not necessary to obtain informed consent.

Magnetic resonance imaging (MRI)
MRI scans were taken on a Philips 1.5 Tesla MRI system (Koninklijke
Philips N. V. Amsterdam, The Netherlands). Post-gadolinium contrast brain MRIs with special attention to the pituitary gland were
reviewed for the presence of pituitary cysts. Image slices of 1–2 mm
thickness were used for both sagittal and coronal images. Fluid-filled
lesions were defined as cysts and were only distinguishable by size,
and an identified mass was considered an adenoma and excluded
from the study. Patients were referred for dynamic scanning when
a lesion could not be classified otherwise. Pituitary and cyst length
and height were measured using mid-sagittal images, while width
was obtained using coronal images at the level of the pituitary stalk
entrance into the gland. Pituitary volumes and cyst volumes were
calculated using the ellipsoidal formula (l × w × h)/2. Percentage of
the gland occupied by the cyst (POGO) was calculated with the formula (cyst volume/pituitary volume) × 100. A cyst with a POGO less
than 15% was defined as a small cyst, and a POGO greater than 15%
was defined as a large cyst.

Statistical analysis
All statistical analyses were performed using IBM SPSS software
(IBM Corp. Armonk, NY, USA). Continuous variables were compared using the two-tailed Student’s t-test and were presented as
the mean ± standard deviation. Categorical variables were compared
using the chi-squared (χ2) test. A p-value <0.05 was considered statistically significant.

Ethical approval
The research related to human use has complied with all the relevant national regulations, institutional policies and is in accordance
with the tenets of the Helsinki Declaration. The Institutional Review
Board of New York Medical College approved this cross-sectional
retrospective study.

Results
Table 1 depicts the prevalence of cysts stratified by the
demographics of sex and age groups. Table 2 compares
cyst volume and POGO, separated by diagnosis and age
groups. Table 3 compares cyst volume and POGO, stratified by sex and diagnosis. Table 4 displays the prevalence
of large and small cysts by diagnosis.
Six hundred and eighteen patients met the criteria for
inclusion in the study. Of these patients, 393 were male
(64%) and 225 were female (36%). Two hundred and sixtysix patients had GHD (43%), of which 181 were male (68%)

Table 1: Demographics and prevalence of pituitary cysts.
Total

n
# with cyst
Prevalence, %
Mean age
(SD age)

GHD

ISS

Total

Male

Female

≤11

>11

Total

Male

Female

Total

Male

Female

618
56
9.1
11.5
(3.4)

393
39
9.9
11.9
(3.5)

225
17
7.5
10.7
(3.2)

233
23
9.87
7.6
(2.9)

385
33
8.57
13.7
(2.0)

266
36
13.5
11.3
(3.4)

181
27
14.9
11.8
(3.5)

85
9
10.6
10.3
(3.2)

352
20
5.7
11.6
(3.4)

212
12
5.7
11.9
(3.5)

140
8
5.7
11.0
(3.1)

SD, standard deviation; GHD, growth hormone deficiency; ISS; idiopathic short stature.
Table 2: Cyst volume and POGO, separated by diagnosis and age group.

n
Mean cyst volume (SD)
p-Value
Mean POGO (SD)
p-Value

Cyst patients

GHD

ISS

≤11

>11

56
51.1 (±58.9)

36
62.0 (±67.2)

23
39.8 (±31.1)

11.7% (±11.3)

15.3% (±12.8)

20
29.4 (±38.4)
0.01
7.1% (±8.0)
0.003

33
58.7 (±71.3)
0.19
10.8% (±10.4)
0.46

13.1% (±12.6)

SD, standard deviation; POGO, percentage of the gland occupied by the cyst; GHD, growth hormone deficiency; ISS; idiopathic short stature.
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Table 3: Volumetry of pituitary cysts by sex and diagnosis.

n
Mean cyst volume (SD)
p-Value
Mean POGO (SD)
p-Value

GHD male

ISS male

GHD female

ISS female

27
68.9 (±74.9)

12
29.5 (±46.7)
0.03
6.7% (±9.0)
0.009

9
41.3 (±29.6)

8
29.2 (±24.1)
0.27
7.8% (±6.6)
0.16

16.4% (±14.3)

11.8% (±5.6)

SD, standard deviation; GHD, growth hormone deficiency; ISS; idiopathic short stature; POGO, percentage of the gland occupied by the cyst.

Table 4: Prevalence of large versus small pituitary cysts in the
different patient diagnoses.

Small cysts
p-Value
Large cysts
p-Value

Cyst patients

GHD

ISS

66.1%

55.6%

33.9%

44.4%

85.0%
0.04
15.0%
0.04

GHD, growth hormone deficiency; ISS; idiopathic short stature.

and 85 were female (32%). Three hundred and fifty-two
had ISS (57%), of which 212 were male (60%) and 140 were
female (40%).

Prevalence
Of the 618 patients studied, 56 had cysts, resulting in an
overall prevalence of 9.1% (Table 1). GHD patients were
found to have a prevalence of 13.5% compared to 5.7%
for ISS patients (p = 0.46). This difference was not significant. The prevalence between males and females of the
entire cohort was not significant (9.9% and 7.5%, p = 0.79).
When analyzed by age, 9.87% of prepubertal patients
(group 1) showed pituitary cysts, while 8.57% of pubertal
patients (group 2) demonstrated a cyst (p = 0.59, Table 1).
The difference in prevalence between age groups was not
significant.

had a larger cyst volume (58.67 mm3 ± 71.29 mm3) than the
group 1 patients (39.76 mm3 ± 31.08 mm3). This difference
was not significant (p = 0.19, Table 2).

POGO
The mean POGO of the cyst for GHD patients was
15.3% ± 12.8 (median 13.5) and for ISS it was 7.1% ± 8.0
(median 4.8). The difference between these two groups
was statistically significant (p = 0.003). For males, the
difference in POGO between the GHD (mean 16.4% ± 14.3,
median 13.5) and ISS (mean 6.7% ± 9.0, median 4.1) groups
was significant (p = 0.009). For females, the difference in
POGO between the GHD (mean 11.8% ± 5.6, median 10.9)
and ISS (mean 7.8% ± 6.6, median 5.4) groups was not
significant (p = 0.16). Mean POGO in group 1 patients was
13.08% ± 12.6 and mean POGO in group 2 patients was
10.77% ± 10.4. This difference was not significant (p = 0.46,
Tables 2 and 3).
In patients who had a pituitary cyst, 66.1% had a
small cyst. For GHD and ISS patients with a cyst, small
cysts were found in 55.6% and 85%, respectively. This
difference was significant (p = 0.04). Large cysts were
found in 33.9% of all patients with a cyst. For GHD and
ISS patients with a cyst, large cysts were found in 44.4%
and 15%, respectively. There was a significant difference
between the percentage of GHD patients and ISS patients
with large cysts (p = 0.04, Table 4).

Cyst volume
Cyst analysis showed a significant difference between cyst
volume in GHD patients (mean 62.0 mm3 ± 67.2, median
48.9) vs. ISS patients (mean 29.4 mm3 ± 38.4, median
16.5) (p = 0.01). For males, the difference in cyst volume
between GHD patients (mean 68.9 mm3 ± 74.9, median
53.7) and ISS patients (mean 29.5 mm3 ± 46.7, median 14.5)
was significant (p = 0.03). Cyst volume was greater in GHD
females (mean 41.3 mm3 ± 29.6, median 34.5) than in ISS
females (mean 29.2 mm3 ± 24.1, median 19.9), but this difference was not significant (p = 0.27). The group 2 patients

Discussion
To the best of our knowledge, the data presented here is the
first study to assess cyst prevalence and volumetry in children with GHD and ISS. Pituitary cysts have been speculated
to cause a variety of clinical findings, including anterior
pituitary dysfunction, visual field defects, and headaches
[11, 14–23]. This pathology may be caused by cyst compression of the adenohypophysis [10–12]. Because somatotrophs are the most abundant cell type of the pituitary
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gland, they are the most likely to be affected by a cyst [10,
24, 25]. Given this relationship, one might hypothesize that
children with poor growth may have a higher prevalence
of cysts than the general pediatric population. However, in
a recently completed study, we found a general pediatric
population prevalence of cysts of 14.6%. This is greater than
the 9.1% prevalence found in this study for short children.
This tends to negate the hypothesis that cyst prevalence
itself is related to poor growth and GHD. However, the difference in prevalence between our two studies is not comparable because higher resolution MRIs were utilized in
the normal children study. Improved MRI technology may
allow for more cysts of smaller size to be detected. The difference in cyst prevalence between GHD, ISS, and normal
stature children warrants further investigation.
Cyst size may be a causative factor in cyst related pituitary dysfunction. We found the mean cyst volume and
POGO of cysts in GHD children to be significantly larger
than in ISS children, implicating larger cysts with increasing pituitary dysfunction. Furthermore, the volume and
POGO of cysts in normal children [10] tended to be smaller
than those of this study, with a mean volume and POGO of
17.28 mm3 and 4.87%, respectively, in comparison to GHD
(62 mm3, 15.3%) and ISS (29.4 mm3, 7.1%) patients.
Although cyst volume was greater in pubertal patients
than prepubertal patients (p = 0.19), the difference in POGO
between age groups was not significant (p = 0.46). This is
likely because the pituitary size increases significantly in
adolescence [26, 27]. If the POGO does not change, that is
potentially indicative of only an increase in pituitary size,
not an increase of cyst impingement on the gland.
From this data, we speculate that small cysts may
be of a physiologic nature that come and go, but as cysts
become larger, they may have a negative effect on pituitary secretion and cause problems with normal growth,
with the larger cysts causing GHD.
It should be noted that the difference in POGO was
not significant between GHD and ISS females. This is
likely due to a lower number of females in our study. As
our study was retrospective, we were unable to account
for pubertal stage. We acknowledge that careful Tanner
staging is essential to future research. Additional research
looking at pituitary cysts and GH production in children
may include genetic analysis.
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